Search results
Cathie Wood Darling Exact Sciences, And Rival Guardant Health, Dip On Colon Cancer Updates
Investor's Business Daily· 2 months agoShares of Guardant Health and Exact Sciences skidded early Thursday after the companies unveiled...
1 Beaten-Down Cathie Wood Stock to Buy and Hold
Motley Fool via Yahoo Finance· 1 month agoCancer diagnostic specialist Exact Sciences (NASDAQ: EXAS) has lagged the market over the past three years. The pandemic and the economic troubles that...
Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM
Zacks via Yahoo Finance· 2 months agoExact Sciences Corporation EXAS recently announced the online publication of the BLUE-C study...
Exact Sciences Rockets As Guardant's Blood Test Pales Vs. Cologuard
Investor's Business Daily· 1 year agoGuardant Health unveiled pivotal results for its colon cancer-detecting blood test that lagged rival...
Cathie Wood Is Selling This Stock: Should You?
Motley Fool via Yahoo Finance· 3 months agoSome investors are famous enough that their every move is scrutinized. That's the case with Cathie Wood, CEO of Ark Invest, an investment management...
2 Beaten-Down Cathie Wood Stocks With Massive Potential
Motley Fool via Yahoo Finance· 2 months agoEven companies with solid prospects sometimes fail to keep pace with the market. When that happens,...
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
Investor's Business Daily· 2 months agoExact Sciences stock surged to a seven-month high Tuesday after the company's colon cancer-screening...
Where Will Exact Sciences Be in 5 Years?
Motley Fool· 8 months agoOver the past five years, Exact Sciences (NASDAQ: EXAS) hasn't delivered great returns. Exact Sciences develops cancer diagnostic tests. It is best known...
Exact Sciences says its new colon cancer test shows 30% lower false positive rate
Reuters via Yahoo News· 11 months agoThe company said it plans to complete submission of its marketing application for the new test to...
Down 40% in 2022, Can Exact Sciences Recover in 2023?
Motley Fool· 1 year agoInvestors are attracted to its leading position in the market for early cancer detection, but the...